132 related articles for article (PubMed ID: 36227685)
1. Circulating cell-free-DNA concentration is a good biomarker for diagnosis of colorectal cancer in Mexican patients.
Saucedo-Sariñana AM; Lugo-Escalante CR; Barros-Núñez P; Marín-Contreras ME; Pineda-Razo TD; Mariscal-Ramírez I; Gallegos-Arreola MP; Rosales-Reynoso MA
Cell Mol Biol (Noisy-le-grand); 2022 Jun; 68(6):1-8. PubMed ID: 36227685
[TBL] [Abstract][Full Text] [Related]
2. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.
El Messaoudi S; Mouliere F; Du Manoir S; Bascoul-Mollevi C; Gillet B; Nouaille M; Fiess C; Crapez E; Bibeau F; Theillet C; Mazard T; Pezet D; Mathonnet M; Ychou M; Thierry AR
Clin Cancer Res; 2016 Jun; 22(12):3067-77. PubMed ID: 26847055
[TBL] [Abstract][Full Text] [Related]
3. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
[TBL] [Abstract][Full Text] [Related]
4. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer.
Mouliere F; El Messaoudi S; Pang D; Dritschilo A; Thierry AR
Mol Oncol; 2014 Jul; 8(5):927-41. PubMed ID: 24698732
[TBL] [Abstract][Full Text] [Related]
5. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
[TBL] [Abstract][Full Text] [Related]
6. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer.
Hao TB; Shi W; Shen XJ; Qi J; Wu XH; Wu Y; Tang YY; Ju SQ
Br J Cancer; 2014 Oct; 111(8):1482-9. PubMed ID: 25157833
[TBL] [Abstract][Full Text] [Related]
7. Cell-free circulating ALU repeats in serum have a prognostic value for colorectal cancer patients.
Anzinger I; Nagel D; De Toni EN; Ofner A; Philipp AB; Holdt LM; Teupser D; Kolligs FT; Herbst A
Cancer Biomark; 2023; 37(4):237-248. PubMed ID: 37302022
[TBL] [Abstract][Full Text] [Related]
8. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.
Bergheim J; Semaan A; Gevensleben H; Groening S; Knoblich A; Dietrich J; Weber J; Kalff JC; Bootz F; Kristiansen G; Dietrich D
Br J Cancer; 2018 May; 118(9):1217-1228. PubMed ID: 29610456
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience.
Li M; Jia Y; Xu J; Cheng X; Xu C
Ann Hematol; 2017 Aug; 96(8):1343-1351. PubMed ID: 28623396
[TBL] [Abstract][Full Text] [Related]
10. The value of the plasma circulating cell-free DNA concentration and integrity index as a clinical tool for prostate cancer diagnosis: a prospective case-control cohort study in an Iranian population.
Khani M; Hosseini J; Mirfakhraie R; Habibi M; Azargashb E; Pouresmaeili F
Cancer Manag Res; 2019; 11():4549-4556. PubMed ID: 31191016
[No Abstract] [Full Text] [Related]
11. Comparison of methods for isolation and quantification of circulating cell-free DNA from patients with endometriosis.
Huebner H; Lubrich H; Blum S; Antoniadis S; Lermann J; Ekici A; Fasching PA; Beckmann MW; Ruebner M; Burghaus S
Reprod Biomed Online; 2021 Nov; 43(5):788-798. PubMed ID: 34493460
[TBL] [Abstract][Full Text] [Related]
12. Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles.
Yasui K; Toshima T; Inada R; Umeda Y; Yano S; Tanioka H; Nyuya A; Fujiwara T; Yamada T; Naomoto Y; Goel A; Nagasaka T
Mol Cancer; 2024 Jan; 23(1):1. PubMed ID: 38172877
[TBL] [Abstract][Full Text] [Related]
13. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
[No Abstract] [Full Text] [Related]
14. Comprehensive Evaluation of the Factors Affecting Plasma Circulating Cell-Free DNA Levels and Their Application in Diagnosing Nonsmall Cell Lung Cancer.
Chen Z; Zhang S; Li C; Xu C; Zhao J; Miao L
Genet Test Mol Biomarkers; 2019 Apr; 23(4):270-276. PubMed ID: 30986099
[TBL] [Abstract][Full Text] [Related]
15. Circulating cell-free DNA in serum as a biomarker of colorectal cancer.
da Silva Filho BF; Gurgel AP; Neto MÁ; de Azevedo DA; de Freitas AC; Silva Neto Jda C; Silva LA
J Clin Pathol; 2013 Sep; 66(9):775-8. PubMed ID: 23833048
[TBL] [Abstract][Full Text] [Related]
16. Quantification of mitochondrial cfDNA reveals new perspectives for early diagnosis of colorectal cancer.
Linke C; Hunger R; Reinwald M; Deckert M; Mantke R
BMC Cancer; 2023 Mar; 23(1):291. PubMed ID: 36997875
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA.
Shi X; Duose DY; Mehrotra M; Harmon MA; Hu P; Wistuba II; Kopetz S; Luthra R
Cancer Genet; 2019 Sep; 237():82-89. PubMed ID: 31447070
[TBL] [Abstract][Full Text] [Related]
18. Analysis of colorectal cancer-related mutations by liquid biopsy: Utility of circulating cell-free DNA and circulating tumor cells.
Takeda K; Yamada T; Takahashi G; Iwai T; Ueda K; Kuriyama S; Koizumi M; Matsuda A; Shinji S; Ohta R; Yokoyama Y; Hotta M; Hara K; Yoshida H
Cancer Sci; 2019 Nov; 110(11):3497-3509. PubMed ID: 31465598
[TBL] [Abstract][Full Text] [Related]
19. Integrity and quantity of salivary cell-free DNA as a potential molecular biomarker in oral cancer: A preliminary study.
Rapado-González Ó; López-Cedrún JL; Lago-Lestón RM; Abalo A; Rubin-Roger G; Salgado-Barreira Á; López-López R; Muinelo-Romay L; Suárez-Cunqueiro MM
J Oral Pathol Med; 2022 May; 51(5):429-435. PubMed ID: 35416334
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of circulating cell free DNA in plasma as a biomarker of different thyroid diseases.
Caglar O; Cilgin B; Eroglu M; Cayir A
Braz J Otorhinolaryngol; 2020; 86(3):321-326. PubMed ID: 30826312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
